Clearside Biomedical, Inc. announced the filing of a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code.
The company intends to maximize stakeholder value through a structured process.
Clearside's assets include the SCS Microinjector Delivery Platform and promising clinical development programs.
Structured Sale Process
The company plans to undergo a voluntary Chapter 11 process to facilitate a strategic sale of its assets.
SCS Microinjector Platform
Clearside's SCS Microinjector platform, along with licensing agreements, presents valuable assets for potential buyers.
CLS-AX Program
The CLS-AX program includes Phase 3-ready assets for Wet AMD and a trial path for Diabetic Retinopathy treatment.
IND-Ready Programs
Clearside's programs targeting Geographic Atrophy and Diabetic Macula Edema are poised for further development.
- Clearside aims to continue normal operations during the Chapter 11 process.
- The company's focus on structured asset sale and continued development signals determination to maximize value for stakeholders.
Clearside Biomedical's decision to pursue a strategic sale through Chapter 11 reflects a commitment to enhancing stakeholder value and leveraging its innovative delivery platform and clinical programs.